Table 2 Drug-drug interactions and predicted plasma levels of antiarrhythmics and targeted cancer therapies
From: Management of atrial fibrillation in patients taking targeted cancer therapies
| Anti-arrhythmics | |||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Vaughan Williams Class | 1a | 1b | 1c | 2 | 3 | 4 | Misc. | ||||||||||||||||
| Quin-idine | Diso-pyra-mide | Procai-namide | Lido-caine | Mexil-etine | Flec-ainide | Propa-fenone | Meto-prolol | Aten-olol | Carve-dilol | Labe-talol | Propr-anolol | Nad-olol | Pind-olol | Sotalol | Dofet-ilide | Ibut-ilide | Amio-darone | Drone-darone | Diltia-zem | Verap-amil | Digo-xin | ||
|
Tyrosine Kinase Inhibitors | Afatinib | TA D | TA D | T D | A | TA D | T D | B | TA D | B | |||||||||||||
| Axitinib | T* | T* | T* | ||||||||||||||||||||
| Bosutinib | T | Q | Q | Q | Q | T | T | A | Q | Q | Q | T | T | T | T | A | |||||||
| Cabozantinib | A | A | A | TA | T* | T* | T* | A | |||||||||||||||
| Ceritinib | Q | Q | Q | T | Q | B/Q | B | B | B | B | B | B | B | B/Q | Q | Q | B/Q | A/B/Q* | B* | B* | B | ||
| Crizotinib | Q | Q | Q | A | Q | A/Q | B | B | TA/B | B | TA/B | A/B | B | Q | Q | Q | Q | Q | TA/B | TA/B | A/B | ||
| Dasatinib | A/Q | A/Q | Q | A | Q | Q | A | A | Q | A/Q | Q | A/Q | TA/Q* | TA* | TA* | A | |||||||
| Erlotinib | T/D | T* | T* | T D | |||||||||||||||||||
| Gefitinib | T | A | T | T | T | T | |||||||||||||||||
| Ibrutinib | A | A | A | TA | T/D | TA/D | TA* | A | |||||||||||||||
| Imatinib | TA | A | A | A | A | TA | TA | A | A | TA | TA | TA | TA | A | |||||||||
| Lapatinib | TA/Q | Q | Q | Q | Q | TA | T | A | Q | A/Q | Q | TA/Q | T/Q* | TA* | TA* | A | |||||||
| Lenvatinib | Q | Q | Q | Q | Q | T | T | Q | Q | Q | Q | Q | T | T | |||||||||
| Nilotinib | Q | Q | Q | A | A | Q | Q | A | TA | TA | A | A | Q | Q | Q | Q | Q* | TA* | TA* | A | |||
| Osimertinib | Q | Q | Q | A | A | A/Q | A/Q | TA | TA | Q | Q | Q | Q | Q | TA | TA | A | ||||||
| Pazopanib | T/Q | Q | Q | Q | Q | A | T | T | Q | Q | Q | T/Q | T/Q* | T* | T* | ||||||||
| Ponatinib | T/A | TA | T | A | TA | T* | TA* | TA* | A | ||||||||||||||
| Regorafenib | A | B | B | A/B | B | B | A/B | B | B | A/B | T/B | TA/B | TA/B | A/B | |||||||||
| Ruxolitinib | B | B | B | B | B | B | B | B | B | B | T/B* | T/B* | T/B* | B | |||||||||
| Sorafenib | A/Q | Q | Q | A | Q | Q | A | Q | Q | Q | Q | T/Q | TA | TA | |||||||||
| Sunitinib | A/Q | Q | Q | Q | Q | A | A | Q | Q | Q | A/Q | T/Q* | TA* | TA* | A | ||||||||
| Vandetanib | Q | Q | Q | Q | Q | A | A | Q | Q | Q | Q | Q | TA | TA | A | ||||||||
- Drug-drug interactions are predicted based on pharmacokinetics, given the limited data available from patient studies
- Underlined = "Alter combination" Bold = "Combination is contraindicated"
-
